OTCMKTS:NBIO Nascent Biotech (NBIO) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free NBIO Stock Alerts $0.10 +0.01 (+11.12%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.10▼$0.1050-Day Range$0.09▼$0.1852-Week Range$0.03▼$0.28Volume1,700 shsAverage Volume79,815 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Nascent Biotech alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Nascent Biotech Stock (OTCMKTS:NBIO)Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.Read More NBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIO Stock News HeadlinesApril 25, 2024 | americanbankingnews.comNascent Biotech (OTCMKTS:NBIO) Stock Crosses Below 50 Day Moving Average of $0.12April 16, 2024 | msn.comNascent Biotech prepares for pivotal Phase II research with fresh manufacturing runApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…April 16, 2024 | finanznachrichten.deNascent Biotech Inc.: Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing RunApril 15, 2024 | americanbankingnews.comNascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Up 21.8% in MarchMarch 19, 2024 | finanznachrichten.deNascent Biotech Inc.: Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery SystemMarch 2, 2024 | morningstar.comNascent Biotech Inc NBIOFebruary 6, 2024 | finanznachrichten.deNascent Biotech Inc.: Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug ConjugatesApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 6, 2024 | finance.yahoo.comNascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug ConjugatesJanuary 10, 2024 | finanznachrichten.deNascent Biotech Inc.: Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under ValuedJanuary 9, 2024 | finance.yahoo.comNascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under ValuedDecember 19, 2023 | finance.yahoo.comNascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution RiskNovember 29, 2023 | finance.yahoo.comNascent Biotech Granted Japanese Patent for Crossing Blood-Brain BarrierNovember 15, 2023 | usnews.comIsana Nascent AcademyOctober 26, 2023 | bizjournals.comChicago to showcase its biotech sector at capital summit next weekSeptember 2, 2023 | washingtonpost.comA tropical storm could threaten Florida next week. Here’s what we know.August 22, 2023 | finance.yahoo.comNascent Biotech to Begin Phase II Clinical Trials for Brain CancerJune 7, 2023 | finanznachrichten.deNascent Biotech Inc.: Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual MeetingMay 26, 2023 | finanznachrichten.deNascent Biotech Inc.: Nascent Biotech Regains Worldwide Rights for PritumumabMay 26, 2023 | finance.yahoo.comNascent Biotech Regains Worldwide Rights for PritumumabMay 9, 2023 | finanznachrichten.deNascent Biotech Inc.: Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual MeetingMay 9, 2023 | finance.yahoo.comNascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual MeetingApril 18, 2023 | finanznachrichten.deNascent Biotech Inc.: Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and ApprovalApril 18, 2023 | finance.yahoo.comNascent Submits Phase 2 Clinical Research Protocol to FDA for Review and ApprovalFebruary 28, 2023 | finanznachrichten.deNascent Biotech Inc.: Nascent Announces the Completion of Its Phase1 Clinical TrialsFebruary 28, 2023 | finance.yahoo.comNascent Announces the Completion of Its Phase1 Clinical TrialsSee More Headlines Receive NBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nascent Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Next Earnings (Estimated)6/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NBIO CUSIPN/A CIK1622057 Webwww.nascentbiotech.com Phone(612) 961-5656FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Sean Carrick (Age 56)President, CEO, Secretary & Director Comp: $252kMr. Lowell Holden (Age 81)CFO, Chief Accounting Officer & Director Comp: $180kDr. Mark C. Glassy Ph.D. (Age 72)Founder Comp: $43kDr. Navpaul Singh M.D.Chief Medical ConsultantKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors NBIO Stock Analysis - Frequently Asked Questions How have NBIO shares performed in 2024? Nascent Biotech's stock was trading at $0.1729 on January 1st, 2024. Since then, NBIO shares have decreased by 42.2% and is now trading at $0.0999. View the best growth stocks for 2024 here. Are investors shorting Nascent Biotech? Nascent Biotech saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 17,900 shares, an increase of 21.8% from the March 15th total of 14,700 shares. Based on an average daily trading volume, of 27,100 shares, the days-to-cover ratio is presently 0.7 days. View Nascent Biotech's Short Interest. When is Nascent Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Saturday, June 29th 2024. View our NBIO earnings forecast. What other stocks do shareholders of Nascent Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nascent Biotech investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Evelo Biosciences (EVLO), Kaleido Biosciences (KLDO). How do I buy shares of Nascent Biotech? Shares of NBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NBIO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport SocietyMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nascent Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
